Îä´óѧÕßCell Stem Cell·¢ÏÖALKBH5Ñ¡ÔñÐÔµ÷¿Ø°×Ѫ²¡¸Éϸ°û¹¦ÄܵķÖ×Ó»úÖÆ
Î人´óѧÃâÒßÓë´úÐ»Ç°ÑØ¿ÆÑ§ÖÐÐÄ£¯Ò½Ñ§Ñо¿ÔºÕźý¨½ÌÊÚÑо¿ÍŶÓÔÚCell Stem Cell¡¶Ï¸°û•¸Éϸ°û¡··¢±í×îÐÂÑо¿³É¹û£¬½éÉÜÁËALKBH5Ñ¡ÔñÐÔµ÷¿Ø°×Ѫ²¡¸Éϸ°û¹¦ÄܵķÖ×Ó»úÖÆ£¬¸ÃÑо¿¶ÔÓÚ°ÐÏò°×Ѫ²¡¸Éϸ°û¼°¼±ÐÔËèϵ°×Ѫ²¡ÁÙ´²ÖÎÁƾßÓÐÖØÒªÒâÒå¡£
ÂÛÎÄÌâΪ¡°Leukemogenic Chromatin Alterations promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis¡±£¨¡¶È¾É«Öʸıäͨ¹ýKDM4C-ALKBH5-AXLÐźÅÖá´Ù½ø¼±ÐÔËèϵ°×Ѫ²¡¸Éϸ°û¹¦ÄÜά³Ö¡·£©¡£Õźý¨Îª¸ÃÂÛÎĵÄͨѶ×÷Õߣ¬Ò½Ñ§Ñо¿Ôº²©Ê¿Ñо¿ÉúÍõ¼Îìõ¡¢ÍõÅàÅà¡¢º«¹úÇ¿ºÍÎ人´óѧ¿ÚǻҽѧԺ²©Ê¿Ñо¿ÉúÀîÒ»´åΪ¸ÃÂÛÎĵĹ²Í¬µÚÒ»×÷Õß¡£
¼±ÐÔËèϵ°×Ѫ²¡£¨AML£©ÊÇ×î³£¼ûµÄ¶ñÐÔѪҺϵͳÖ×Áö£¬ÆðÔ´ÓÚÕý³£ÔìѪ¸É×æÏ¸°ûµÄ°×Ѫ²¡¸Éϸ°û¡£ÕâÀàϸ°û¾ßÓÐÄÍÒ©ÐÔ£¬ÎÞ·¨±»ÁÙ´²³£¹æµÄ»¯ÁÆÊÖ¶ÎËùÇå³ý£¬ÊǼ±ÐÔËèϵ°×Ѫ²¡·¢Éú·¢Õ¹¡¢ÄÍÒ©Ó븴·¢µÄÖ÷ÒªÔÒò¡£Òò´Ë£¬²ûÃ÷°×Ѫ²¡¸Éϸ°ûÌØÒìµÄ¹¦Äܵ÷¿Ø»úÖÆ£¬¶ÔÓÚ°ÐÏò°×Ѫ²¡¸Éϸ°û¼°¼±ÐÔËèϵ°×Ѫ²¡ÁÙ´²ÖÎÁƾßÓÐÖØÒªÒâÒå¡£Ñо¿ÍŶÓÊ×ÏÈͨ¹ý×éѧ·ÖÎö·¢ÏÖ£¬ÔÚ°×Ѫ²¡¸Éϸ°û·¢Éú¹ý³ÌÖÐALKBH5±àÂëÇøÓòµÄȾɫÖÊ¿ª·ÅÐÔ£¬ALKBH5±í´ïˮƽÉý¸ß¡£Í¬Ê±·¢ÏÖALKBH5±í´ïÓë²»Á¼Ô¤ºó³ÊÕýÏà¹Ø¡£
Ñо¿ÍŶӹ¹½¨ÁËÌõ¼þÐÔÇóýСÊó£¬ÀûÓü±ÐÔËèϵ°×Ѫ²¡Ð¡ÊóÄ£Ðͺͼ±ÐÔËèϵ°×Ѫ²¡»¼ÕßÀ´Ô´µÄpDXÄ£ÐÍ£¬·¢ÏÖALKBH5ÊÇά³Ö°×Ѫ²¡¸Éϸ°û¹¦ÄÜËù±ØÐèµÄ£¬µ«¶ÔÕý³£ÔìѪ¹¦ÄÜÎÞÃ÷ÏÔÓ°Ïì¡£½øÒ»²½Ñо¿·¢ÏÖ×éµ°°×È¥¼×»ù»¯Ã¸KDM4Cͨ¹ý½µµÍH3K9me3ˮƽÀ´Ôö¼ÓALKBH5»ùÒò×ùµÄȾɫÖÊ¿ª·ÅÐÔ£¬´Ù½øMYBºÍpol IIµÄ=À´Éϵ÷ALKBH5µÄ±í´ï¡£ »¹·¢ÏÖALKBH5ͨ¹ýµ÷¿ØÏÂÓÎAXLµÈmRNAµÄÎȶ¨ÐÔÀ´·¢»ÓÆäÔÚ°×Ѫ²¡¸Éϸ°ûÖеŦÄÜ¡£
¸ÃÑо¿½«È¾É«ÖÊ״̬µÄ¸Ä±äÓëm6AÐÞÊλùÒòµÄ±í´ïµ÷¿ØÁªÏµÆðÀ´£¬Í¬Ê±½ÒʾÁËALKBH5ÔÚÑ¡ÔñÐÔµØÎ¬³ÖAML LSCs¹¦ÄÜÖеÄ×÷Óü°Æä·Ö×Ó»úÖÆ£¬ÎªÁÙ´²ÉÏÌØÒìÐԵذÐÏòLSCs¶øÖÎÓú¼±ÐÔËèϵ°×Ѫ²¡ÌṩÁËÀíÂÛ»ù´¡£¬¾ßÓÐÖØÒªµÄÁÙ´²×ª»¯¼ÛÖµ¡£
´ËÍ⣬±¾Ñо¿µÃµ½ÃÀ¹úÂíÈøÖîÈû´óѧҽѧԺÀîÉÙ¹â½ÌÊÚ¡¢»ªÖпƼ¼´óѧкÍÒ½ÔºÁõÁ貨½ÌÊÚºÍÀîÀÙ½ÌÊÚ¡¢Î人´óѧÖÐÄÏÒ½ÔºÖÜܽÁá½ÌÊÚºÍÖйúҽѧ¿ÆÑ§ÔºÌì½òѪҺѧÑо¿Ëù³Ì»Ô½ÌÊڵİïÖú¡£
ÔÎıêÌ⣺
Leukemogenic Chromatin Alterations promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis